title: Metabolic control and therapeutic profile of patients with diabetes in Portuguese primary care (TEDDI CP).
abstract: OBJECTIVE
  To evaluate the metabolic control rate and to characterize the therapeutic profile of patients with Type 2 diabetes mellitus (DM2) from Portuguese primary care of National Health Service.
  
  
  METHODS
  Cross-sectional multicentre study conducted in Portuguese primary health care units between July 2011 and May 2012. A national representative sample of 1528 DM2 patients was selected from 51 units, stratified by region. Socio-demographic, anthropometric, lifestyle, cardiometabolic risk factors, disease status, HbA1c levels and therapeutic information were collected.
  
  
  RESULTS
  Patients' mean age was 65±10.7 years (50.4% males) and median duration of disease was 7 years: range (0-45 years). Almost 8% were smokers, 80.3% had hypertension, 61.6% hypercholesterolemia and almost 15% cardiovascular disease. Patients' health condition was classified with a score of 4 or 5 (excellent) for 60.6%. Median HbA1c was 6.6% (min-max: 4.2%-13.4%), 64.8% of the patients had HbA1c<7.0% and 49.2% HbA1c≤6.5%. Oral antidiabetics were used in 94.4% of the patients, antihypertensives in 80.6%, antidyslipidemics in 72.0%, antiplatelet agents in 50.6% and insulin in 8.3%.
  
  
  CONCLUSIONS
  Metabolic control rate was good according to current guidelines. However, patients with higher HbA1c levels had longer time since diagnosis, worse current health condition, hypertriglyceridemia and were insulin-treated.
authors.affiliation: University of Coimbra Medical School, Coimbra, Portugal. Electronic address: massanocardoso@hotmail.com.
authors.forename: Salvador Massano
authors.initials: SM
authors.lastname: Cardoso
authors.affiliation: Department of Endocrinology, Centro Hospitalar S. João, EPE and Porto University, Faculty of Medicine, Porto, Portugal.
authors.forename: Elisabete
authors.initials: E
authors.lastname: Rodrigues
authors.affiliation: Director of Endocrinology Service, Hospital Beatriz Angelo, Loures, Portugal.
authors.forename: Cristina
authors.initials: C
authors.lastname: Valadas
authors.affiliation: General Practitioner, Garcia de Orta Family Health Unit, Porto, Portugal.
authors.forename: Clara
authors.initials: C
authors.lastname: Fonseca
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D015897:Comorbidity; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006304:Health Status; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000453:epidemiology; D006973:Hypertension / Q000188:drug therapy / Q000453:epidemiology; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007267:Injections; D007328:Insulin / Q000008:administration & dosage*; D016014:Linear Models; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009313:National Health Programs; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011174:Portugal / Q000453:epidemiology; D015995:Prevalence; D011320:Primary Health Care; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D015415:Biomarkers; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D007328:Insulin; D010975:Platelet Aggregation Inhibitors; C517652:hemoglobin A1c protein, human
keywords: HbA(1c); Prevalence; Primary care; Type 2 diabetes